The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer.
 
Marcia S. Brose
Honoraria - Bayer
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Genzyme; Loxo; Novartis
Research Funding - Bayer (Inst); Blueprint Medicines (Inst); Eisai (Inst); Exelixis (Inst); Loxo (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Pfizer; UpToDate
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Caris Life Sciences; Fujifilm; Genentech/Roche; HERON; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Sanofi
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; US Oncology
 
Christopher DiSimone
No Relationships to Disclose
 
Sharad K. Jain
Stock and Other Ownership Interests - ABBVIE; ABBVIE (I); AstraZeneca; AstraZeneca (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CELGENE; CELGENE (I); Clovis Oncology; Clovis Oncology (I); crispr therapeutics; crispr therapeutics (I); Editas Medicine; Editas Medicine (I); Exelixis; Exelixis (I); Gilead Sciences; GILEAD SCIENCES (I); Immunomedics; Immunomedics (I); Loxo; Loxo (I)
Consulting or Advisory Role - AstraZeneca; HERON; IMMUNOMEDICS
Travel, Accommodations, Expenses - IMMUNOMEDICS
 
Donald A. Richards
Consulting or Advisory Role - Boehringer Ingelheim; Insys Therapeutics; IntegraGen; Lilly; Merrimack; Pharmacyclics
Speakers' Bureau - Celgene
 
Carlos A. Encarnacion
No Relationships to Disclose
 
Drew W. Rasco
Employment - START
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; TaiRx, Inc.
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Birdie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Santa Maria Biotherapeutics (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Asana Biosciences
 
Robert Charles Shumaker
Employment - Eisai; RRD International (I)
 
Corina E. Dutcus
Employment - Eisai
Leadership - Eisai
Research Funding - Eisai
Travel, Accommodations, Expenses - Eisai
 
Daniel E. Stepan
Employment - Eisai
 
Matthew Guo
Employment - Eisai
 
Emmett V. Schmidt
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Matthew H. Taylor
Consulting or Advisory Role - ArQule; Array BioPharma; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Loxo; Novartis
Speakers' Bureau - Bristol-Myers Squibb; Eisai